hinya Yamanaka received the Nobel Prize for Medicine or Physiology in 2012 for his discovery that the forced expression of the transcription factors Oct4, Sox2, Klf4, and cMyc can induce nuclear reprogramming of somatic cells to induced pluripotent stem cells (iPSCs). 1, 2 We recently discovered that the retroviral vectors used in nuclear reprogramming are more than mere vehicles for the transcription factors. Indeed, by activating innate immune signaling (through Toll-like receptor 3 [TLR3]), these viral vectors cause global changes in the expression and activity of epigenetic modifiers. Specifically, viral double-stranded RNA stimulated TLR3-activated transcriptional pathways (mediated by nuclear factor-κB and IRF3) that caused global changes in epigenetic modifiers (eg, downregulation of the histone deacetylase family and upregulation of histone acetyltransferases). The altered expression of epigenetic enzymes favored histone modifications that facilitated activation of endogenous genes in the core pluripotency network. 3 Finally, as demonstrated by gain-and loss-of-function studies, innate immune signaling also participated in the induction of pluripotency with the use of other methods, including modified messenger RNA-based reprogramming and reprogramming of somatic cells containing the doxycycline-inducible cassette encoding Oct4, Sox2, Klf4, and cMyc.
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Dr Yamanaka's discovery has stimulated others to search for sets of transcriptional factors that may induce transdifferentiation to another somatic cell type, also known as direct reprogramming. Indeed, several groups have converted fibroblasts to neurons, 4 cardiomyocytes, 5 or ECs 6,7 by overexpressing specific transcription factors. In each of these cases, transdifferentiation was induced with the use of viral vectors encoding transcription factors. However, for clinical applications, it would be more desirable to develop strategies that avoid
Sayed et al Innate Immunity Pathway in Transdifferentiation 301
genetic manipulation. Accordingly, we sought to demonstrate that safe and functional ECs can be generated from fibroblasts using small molecules alone. Cognizant of the role of innate immunity in nuclear reprogramming and its directed manipulation to increase epigenetic plasticity, we hypothesized that activation of TLR3, together with inductive growth cues, may be sufficient to induce the transdifferentiation of fibroblasts into ECs (induced ECs [iECs] ).
Methods

Cell Culture and iEC Generation
BJ human newborn foreskin fibroblast cells (Stemgent), tail-tip fibroblasts isolated from 6-week-old Tie2GFP knockin and TLR3 knockout mice, were cultured and maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and 1% penicillin/ streptomycin (5% CO 2 , 37°C). Human dermal microvascular endothelial cells (HMVECs) (Lonza) were cultured with endothelial cell growth medium 2MV (EGM-2) (Lonza). For iEC generation, BJ fibroblasts were seeded on gelatin-coated plates, and, after overnight culture, cells were treated with Poly I:C (30 ng/mL), and the medium was changed to Dulbecco's modified Eagle's medium with 7.5% fetal bovine serum and 7.5% knockout serum replacement. With daily treatments of Poly I:C for 7 days, the medium was gradually transitioned to contain 10% knockout serum replacement. After these treatments, cells were treated with transdifferentiation medium containing 20 ng/mL bone morphogenetic protein-4 (Peprotech), 50 ng/mL vascular endothelial growth factor (VEGF) (Peprotech), and 20 ng/mL basic fibroblast growth factor (BD Bioscience) for another 7 days. Transdifferentiation medium was changed every 2 days. For maintenance of transdifferentiation, the cells were cultured for another 2 weeks in the presence of basic fibroblast growth factor, VEGF, and 0.1 mmol/L 8-bromoadenosine-3′:5′-cyclic monophosphate sodium salt (8-Br-cAMP) (Sigma), with the medium changed every 2 days.
Fluorescence-Activated Cell Sorting
On day 28 of transdifferentiation, the iECs were purified with the use of fluorescence-activated cell sorting. Cells were dissociated into single cells with Accutase (Life Technologies) for 5 minutes at 37°C, washed with 1× phosphate-buffered saline containing 5% bovine serum albumin, and passed through a 70-μm cell strainer. Cells were then incubated with either Alexa Fluor 488-conjugated CD31 antibody (eBioscience) or phycoerythrin-conjugated CD144 antibody (eBioscience) for 30 minutes. Isotype-matched antibody served as negative control. The purified iECs were expanded in EGM-2 media and 10 μmol/L SB431542, a specific transforming growth factor-β receptor inhibitor that promotes embryonic stem cell-derived endothelial cell growth and sheet formation. 6, 8 
RNA Extraction and Quantitative Polymerase Chain Reaction
With the use of RNeasy Mini Kit (Qiagen), total RNA was extracted, and quantitative polymerase chain reaction (PCR) was performed with the use of Taqman gene expression assays (Applied Biosystems). Genes associated with the EC phenotype were analyzed with the data normalized to β-actin housekeeping gene and expressed as relative fold changes with the ΔCt method of analysis.
Immunofluorescent Staining
iECs were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, blocked with 1% normal goat serum, and stained for antihuman CD31 (R&D Systems), anti-human CD144 (R&D Systems), anti-human endothelial nitric oxide synthase (eNOS) (BD Transduction Laboratories), anti-human von Willebrand factor (Abcam), and antiKinase Insert Domain Receptor (KDR) (R&D Systems) overnight at 4 o C. After washes with phosphate-buffered saline, the cells were treated with Alexa Fluor 488 or 594 secondary antibodies.
Functional Assays
The functions of the generated iECs were characterized in angiogenic assays and compared with HMVECs and fibroblasts.
Uptake of Acetylated Low-Density Lipoprotein
Uptake of acetylated low-density lipoprotein (LDL) was evaluated by incubating cells with acetylated LDL-594 at 1:200 dilution for 5 hours before the cells were washed with phosphate-buffered saline and the mean fluorescence of the cells in 10 high-power fields was measured.
Vascular Tubelike Formation
The ability of the cells to form tubelike structures was assessed in vitro by seeding 10 4 cells in wells coated with Matrigel in the presence of EGM-2 media containing 50 ng/mL VEGF and incubated for 24 hours.
NO Production
The ability of the cells to produce NO was assessed by measuring the concentration of NO in the culture medium with the use of the NO detection kit (Molecular Probes, Carlsbad, CA) according to the manufacturer's instructions. The amount of nitrate was determined by converting it to nitrite, followed by the colorimetric determination of the total concentration of nitrite as a colored azo dye product of the Griess reaction that absorbed visible light at 540 nm with the use of a microplate reader.
In Vivo Matrigel Angiogenesis Assay
To assess the capacity of the iECs to form functional vessels in vivo, Matrigel was mixed with 5×10 5 iECs in a final volume of 200 μL and injected subcutaneously into the lower abdominal region of SCID mice. After 2 weeks, the Matrigel plugs were dissected, fixed in 4% paraformaldehyde, and stained for human CD31.
Assay for Angiogenic Cytokines
Human angiogenesis proteome profiler antibody arrays (R&D Systems) were used to assess the various cytokines secreted by the iECs in hypoxic conditions. Briefly, iECs were grown in hypoxic conditions (1% O 2 ) for 8 hours, and the conditioned medium was pooled, filtered, and incubated with the antibody cocktail (1:1000) for 1 hour at room temperature. The nitrocellulose membrane was then blocked, and the sample/detection antibody cocktail mixture was added to the membrane. After overnight incubation at 4 o C, the membrane was washed 3 times before incubation with steptavidin horseradish peroxidase (1:2000) for 30 minutes at room temperature. The membranes were then washed before incubation with ECLplus (Amersham, Buckinghamshire, UK). The array data were quantified by densitometry with the use of Image J software.
Chromatin Immunoprecipitation and Chromatin Immunoprecipitation-Quantitative PCR
Quantitative chromatin immunoprecipitation (qChIP) was performed. For qChIP and quantitative reverse transcription PCR, error estimates are SDs. Recovery of genomic DNA as the percent input was calculated as the ratio of copy numbers in the immunoprecipitate to the input control. Primers of CD31 promoter were custom designed and synthesized from Invitrogen, as follows: primer sequence (5′ to 3′), CD31 (F):CGAGACAGAGGGAGGGTCAA; CD31 (R):GGCCTGATATCTCCTCAGGAA.
RNA Sequencing Analysis
RNA seqencing-based expression analysis was performed with the use of RNA samples converted into individual cDNA libraries with the use of Illumina (San Diego, CA). TruSeq methods used single reads of 50 base lengths sequenced at 20 to 30 million read depths with the use of the Illumina HiSeq 2500 instrument. Trimmed sequences were generated as FASTQ outputs and analyzed on the basis of the TopHat/Cufflinks pipeline based on reference annotations produced by the Ensembl Gencode project. Differential and significant gene expression analysis was performed with the use of gene-level FPKM 
Hindlimb Ischemia Model
To assess the therapeutic potential of iECs, we used a murine model of hindlimb ischemia. 10, 11 Briefly, unilateral hindlimb ischemia was induced by ligating the femoral artery of aged-matched NOD-SCID male mice (Jackson Laboratory, 13 weeks old). The mice were randomized into several groups, each receiving either EGM-2 medium (controls) or 10 6 iECs or 10 6 HMVECs intramuscularly in the gastrocnemius muscle (n=5 in each group). To test the survival and localization of iECs, a similar study was performed with intramuscular administration of 10 6 transduced VE-cadherin-expressing iECs. The ischemia score index was obtained based on the following criteria: 0, no changes; 1, discoloration/necrosis of the nails; 2, discoloration/necrosis of the toes; 3, foot necrosis; 4, leg necrosis (up to the gastrocnemius muscle); and 5, autoamputation (loss of limb). There were 2 independent observers blinded to the group assignment. Animal studies were approved by the Administrative Panel on Laboratory Animal Care. Total capillary density of hindlimb cross sections was determined by staining the slides with rabbit anti-mouse CD31 (Abcam), followed by horseradish peroxidase-conjugated secondary antibody. Quantification of capillaries was performed on 4 different fields at a magnification of ×20. The capillary density is normalized to the total number of cells in the field.
Laser Doppler-Based Tissue Perfusion Measurement
Blood flow to the ischemic or normal (nonischemic) hindlimb was assessed with the use of a PeriScan PIM3 laser Doppler system (Perimed AB, Sweden), as described previously. 11 Animals were prewarmed to a core temperature of 37.5°C, and heart rate was monitored constantly for signs of stress from overheating. Hindlimb blood flow was measured preoperativley and postoperatively on selected days (0, 4, 7, 11, 14, and 18). Blood perfusion rate was measured via laser Doppler scans over a 3-minute cycle. The level of perfusion in the ischemic and normal hindlimbs was quantified with the use of the mean pixel value within the region of interest, and the relative changes in hindlimb blood flow were expressed as the ratio of the left (ischemic) over right (normal) laser doppler blood perfusion.
Short Hairpin RNA Design
Short hairpin RNA (shRNA) was obtained from InvivoGen. Target sequences were as follows: TLR3 shRNA, GCTTGGCTTCCACAA CTAGAA.
Statistical Analysis
Data shown are reported as mean±SEM. Differences between groups were calculated by independent t test, 1-way ANOVA corrected with Bonferroni, the Benjamini-Hochberg method, and the MannWhitney nonparametric test when appropriate. In the reverse transcription PCR analyses in which independent samples from those used for RNA sequence were used, correlations were evaluated with Spearman nonparametric correlation analysis, and multivariate regression was used for assessments of independence of correlations. Repeated-measures ANOVA followed by multiple comparisons with the Bonferroni method were used. Statistical significance was accepted at P<0.05.
Results
Direct Reprogramming of Fibroblasts to iECs
To determine whether human fibroblasts could be converted to iECs by the combined activation of innate immunity and EC specification pathways, human foreskin fibroblasts (BJ) were treated with Poly I:C (30 ng/mL) and cultured in a mixture of fibroblast medium and defined growth medium containing knockout serum (induction medium; Figure 1A ). After culture for 7 days in this condition, the medium was changed to transdifferentiation medium supplemented with basic fibroblast growth factor (20 ng/mL), VEGF (50 ng/mL), and bone morphogenetic protein-4 (20 ng/mL), which are known to promote endothelial lineage. 12, 13 To further increase the efficiency of endothelial transdifferentiation, we added 8-Br-cAMP (an agonist of cAMP-dependent protein kinase) to our protocol because it enhances endothelial specification.
14 After 28 days of differentiation, the cells were dissociated and purified for EC-specific marker VE-cadherin or CD31 by fluorescenceactivated cell sorting. Approximately 2% of cells treated with induction and then transdifferentiation media expressed CD31 ( Figure 1B and 1C) . By contrast, in the absence of induction by Poly I:C, transdifferentiation media did not induce the expression of CD31 in any cells.
To further enhance the expansion of iECs, we added SB431542, a specific transforming growth factor-β receptor inhibitor that promotes embryonic stem cell-derived EC growth and monolayer formation. 6, 8 After expansion, the iECs were sorted to 78% purity for CD31 ( Figure IA in the online-only Data Supplement). The iECs formed a typical "cobblestone" monolayer ( Figure IB in the online-only Data Supplement) and continued to express endothelial markers by PCR including CD31, VE-cadherin, KDR, von Willebrand factor, and eNOS ( Figure 1D and Figure IC through IF in the online-only Data Supplement). Similarly, immunofluorescence staining revealed that these iECs were positive for EC markers such as CD31, VE-cadherin, and von Willebrand factor ( Figure 1E and IG in the online-only Data Supplement). These iECs were able to incorporate acetylated LDL and form networks of tubular structures on Matrigel ( Figure 1F and 1G and IG through II in the online-only Data Supplement). Furthermore, when stimulated with acetylcholine or Ca 2+ ionophore A23187, these iECs were capable of generating NO as determined by the Griess reaction ( Figure 1H ). This NO production was comparable to that produced by HMVECs. This increase in NO production was inhibited by L G -nitro-l-arginine methyl ester, a NOS inhibitor, consistent with an active NOS pathway in the iECs ( Figure IJ in the online-only Data Supplement).
To further confirm the function of our iECs, we assessed the cells in vitro for the expression of angiogenic cytokines under hypoxic conditions. Indeed, iECs expressed a majority of the angiogenic cytokines including angiopoietin-1, serpin F1, thrombospondin-1, pentraxin-3, and insulin-like growth factor binding protein-3 ( Figure 1I ). In addition, these iECs showed the capacity to form capillaries when injected subcutaneously in immunodeficient mice after they were placed in Matrigel and growth factor VEGF was added ( Figure 1J ). Furthermore, immunohistochemical images revealed red blood cells in the capillaries formed by the iECs, which indicates that the capillaries were conducting blood ( Figure IK in the online-only Data Supplement). By contrast, when human fibroblasts were subjected to the same in vivo conditions, they did not generate capillary structures.
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derived from Tie2GFP mice. In these mice, green fluorescent protein (GFP) is expressed under the direction of the endothelial-specific receptor tyrosine kinase (Tie2) promoter. To eliminate the possibility of any contaminating ECs in the starting culture of tail-tip fibroblasts, the cells were fluorescence-activated cell sorted to exclude any GFP-positive cells ( Figure 2A ). The GFP-negative tail-tip fibroblasts were then subjected to the induction/transdifferentiation protocol and monitored daily by immunofluorescence for any GFP expression. On day 19, we observed GFP expression in the tail-tip fibroblasts undergoing this protocol, and by day 28 we obtained ≈4% GFP-positive cells ( Figure 2B and 2C) By contrast, when vehicle was substituted for Poly I:C during the induction phase, no GFP-positive cells were obtained with exposure to the Poly I:C-deficient transdifferentiation media at day 19 or 28 ( Figure 2C ). Furthermore, we confirmed the molecular and functional characteristics of these mouse iECs after passaging the cells. Based on gene expression analysis, the mouse iECs resembled murine aortic ECs in their expression of endothelial markers including VE-cadherin, von Willebrand factor, and eNOS ( Figure 2D ). Importantly, these cells showed the capacity to form tubular networks when placed on Matrigel and could incorporate acetylated LDL ( Figure 2E and 2F). When placed in Matrigel and injected subcutaneously in NOD-SCID mice, the mouse iECs were capable of forming capillaries ( Figure 2G ). Human fibroblasts were treated with Poly I:C (30 ng/mL) for 7 days in induction medium containing Dulbecco's modified Eagle's medium/fetal bovine serum and 7.5% knockout serum replacement. After 7 days, the medium was changed to transdifferentiation medium containing Dulbecco's modified Eagle's medium/fetal bovine serum and 10% knockout serum replacement containing 20 ng/mL bone morphogenetic protein-4 (BMP4), 50 ng/mL vascular endothelial growth factor (VEGF), and 20 ng/mL basic fibroblast growth factor (bFGF). After another 7 days, the medium was replaced with endothelial cell growth medium endothelial cell growth medium (EGM-2) containing 50 ng/mL VEGF, 20 ng/mL bFGF, and 0.1 mmol/L 8-bromoadenosine-3′:5′-cyclic monophosphate sodium salt (8-Br-cAMP) for another 14 days. The medium was changed every 2 to 3 days. Cells were then fluorescence-activated cell (FAC) sorted with CD31 and then expanded in EGM-2 medium containing SB431542, a specific transforming growth factor-β receptor inhibitor. B, Fluorescence-activated cell sorting plot data obtained with the use of CD31 + antibody to quantify induced endothelial cells (iECs) (left, vehicle control; right, Poly I:C). C, Fluorescence-activated cell sorting plot data obtained with the use of CD31 + antibody to quantify iECs. All data are represented as mean±SEM (n=3). **P<0.005 vs vehicle control, standard unpaired Student t test. D, Reverse transcription polymerase chain reaction data showing that iECs express endothelial markers CD31 compared with fibroblasts (n=3). *P<0.05, 1-way ANOVA corrected with Bonferroni method. HMVEC indictates human dermal microvascular endothelial cell. E, Immunofluorescence staining of iECs for endothelial markers CD31. F and G, iECs take up acetylated low-density lipoprotein (Ac-LDL) and form capillary-like networks on Matrigel. H, iECs are capable of producing NO in response to acetylcholine (Ach) and Ca 2+ ionophore A23187 (n=3). *P<0.05, 1-way ANOVA corrected with Bonferroni method. I, Angiogenic cytokines are produced by iECs when subjected to hypoxia (n=3, done in duplicate). *P<0.05, 1-way ANOVA corrected with Bonferroni method. IGHBP-3 indicates insulin-like growth factor binding protein-3. J, iECs form blood capillaries (arrows) in subcutaneous Matrigel plugs. The numerous spaces in the figure are the areas of Matrigel that are bounded by the capillaries. We have shown previously that ECs derived from iPSCs (human iPSC-ECs) expressed various markers associated with arterial, venous, and lymphatic ECs and thereby represent a heterogeneous population of ECs. To determine whether iECs derived directly from fibroblasts exhibited all 3 subtypes, we used similar subtype-specific markers for lymphatic, venous, and arterial subtypes of ECs. We found that iECs expressed markers for all 3 subtypes of ECs with high levels for arterial markers (Ephrin B2, Notch 1, and Notch 4) and lower levels for venous (CoupTF-II, EphB4) and lymphatic markers (podoplanin, Prox-1, and LYVE-1; Figure IIA in the onlineonly Data Supplement). These results suggest that transdifferentiated iECs are composed of a heterogeneous population of ECs derived from all 3 subtypes. Furthermore, we provide gene expression data of cells that have undergone the transdifferentiation protocol at day 28 immediately before fluorescence-activated cell sorting ( Figure IIB in the online-only Data Supplement). At this time point, there is no increase in endodermal and ectodermal markers, nor is there expression of pluripotency markers such as Nanog and Oct4. Only the mesodermal (endothelial) markers PECAM1 and DES are increased. Thus, our transdifferentiation protocol appears to be fairly specific for inducing a transdifferentiation within the mesodermal lineage, from fibroblast to EC, without an intermediate pluripotent or progenitor cell.
Histone Modifications During Direct Reprogramming to ECs
To further characterize the epigenetic changes during the induction/transdifferentiation protocol, we performed chromatin immunoprecipitation followed by PCR analysis (ChIP-PCR) to detect trimethylation of histone H3 at lysine 4 (H3K4me3), comparing iECs with parental fibroblasts and HMVECs. This epigenetic modification marks transcriptionally active genes. As expected, we observed a significant increase of H3K4me3 in the promoter regions of CD31 compared with parental fibroblasts ( Figure IIIA in the online-only Data Supplement). Similarly, we assessed histone H3 at lysine 27 (H3K27me3), an epigenetic modification that marks transcriptionally silenced genes, in the same promoter regions of CD31. A concomitant decrease of H3K27me3 was observed at the CD31 promoter regions compared with fibroblasts ( Figure IIIB in the online-only Data Supplement). These epigenetic modifications are consistent with transdifferentiation of fibroblasts to endothelial lineage.
Transcriptional Profiling of iECs
To investigate whether iECs are similar to HMVECs with respect to their global transcriptome, we performed RNA sequence-based expression analysis. RNA samples from independently induced cultures were converted into individual cDNA libraries with the use of the Illumina TruSeq method and then subjected to singleend 50 base-sequence analysis at 20 to 30 million read depths with the use of the Illumina HiSeq 2500 instrument. Trimmed sequences were then generated as FASTQ outputs and analyzed via the TopHat/Cufflinks pipeline [15] [16] [17] on the basis of reference annotations produced by the Ensembl Gencode project. [18] [19] [20] Gene expression analysis was performed with the use of gene-level FPKM expression levels to identify genes that were differentially expressed in iECs and HMVEC versus fibroblasts. The selection criteria for the heat map were either (1) those genes that were expressed at a level >3 FPKM in HMVECS and at least 2-fold greater expression than in fibroblasts or (2) those genes that were expressed at a level >3 FPKM in fibroblasts and at least 2-fold greater expression than in HMVECs (Figure 3 ). The iECs were highly similar to HMVECs in the upregulated and downregulated genes that they shared versus fibroblasts. Indeed, the odds that the overlap of HMVEC and iEC genes was due to chance alone was <10 -100
. Importantly, of the 1085 EC-upregulated genes (by comparison to fibroblasts), 172 are known to be functionally significant for angiogenesis or other endothelial functions (Tables I  and II in the online-only Data Supplement).
Therapeutic Potential of iECs in a Model of Peripheral Arterial Disease
To functionally characterize our iECs and to determine their capacity for vascular regeneration, we induced hindlimb ischemia by ligating the femoral artery of NOD-SCID mice. For noninvasive tracking in vivo, the iECs were transduced with a lentiviral vector carrying the ubiquitin promoter driving firefly luciferase (Fluc). On transplantation into the ischemic limb, the iECs could be detected in the ischemic limb noninvasively by bioluminescence imaging up to day 7 (data not shown). Consistent with our previous studies, 21 we saw a decline in bioluminescence imaging that became undetectable by day 10. Thus, cells were injected again on day 10. The mice were assigned to receive injection (into the gastrocnemius muscle) of either iECs, human ECs (HMVECs), or endothelial growth medium (EGM-2). To assess hindlimb blood flow, laser Doppler perfusion was performed at days 0, 4, 7, 11, 14, and 18 after injection ( Figure IV in the online-only Data Supplement). The hindlimb perfusion ratio (ischemic/control hindlimb perfusion values) was improved in the iEC-treated mice compared with the EGM-2-treated mice ( Figure 4A and 4B) .
To confirm the laser Doppler data, sections of ischemic hindlimbs at day 18 were stained with mouse CD31 antibody to assess capillary density by immunofluorescence. Capillary density was significantly greater in the iEC group compared with the control group ( Figure 4C and 4D and Figure IL in the onlineonly Data Supplement). Furthermore, we assessed the severity of the ischemic tissue damage by assigning a score (by observers blinded to the treatment groups) to the iEC-, HMVEC-, and EGM-2-treated animals. As seen in Figure 4E and 4F, by comparison to media control, injection of iECs improved the clinical score. Taken together, these results indicate that, similar to HMVECS, the iECs promote expansion of the endogenous microvasculature, improve tissue perfusion, and reduce tissue injury.
Innate Immunity Enables Efficient Transdifferentiation of Fibroblasts to ECs
To determine whether TLR3 signaling was necessary for efficient transdifferentiation of human fibroblasts, we repeated the induction/transdifferentiation protocol in BJ fibroblasts treated previously with scrambled shRNA or with shRNA to knockdown the expression of TLR3. After treatment with the induction/transdifferentiation protocol described above, cells were dissociated after 28 days, and fluorescence-activated cells were sorted for VE-cadherin. Notably, TLR3 knockdown reduced iEC generation compared with scramble-treated cells ( Figure 5A and 5B). In addition to reducing iEC generation, TLR3 knockdown impaired the function of iECs. The iECs generated from TLR3 knockdown cells had a significant deficiency in their capacity to take up acetylated LDL ( Figure 5C and 5D) . Furthermore, TLR3 knockdown iECs had a markedly impaired ability to form networks of tubular structures on Matrigel ( Figure 5E and 5F). The functional differences in iECs generated from the TLR3 knockdown cells were associated with some differences in gene and protein expression for EC markers compared with scrambled control (Figure VA through VF in the online-only Data Supplement). To gain more insights into the molecular mechanism underlying the role of innate immunity in transdifferentiation, we performed RNA sequencing on the iECs generated from scramble and TLR3 knockdown fibroblasts. Many of the genes Figure 5G ), which were upregulated in the scramble iECs, were not so in the TLR3 knockdown iECs. Importantly, a variety of genes in which expression was activated in iEC but was prevented from being activated by anti-TLR3 were unaffected by the scrambled vector. For example, angiogenesis essential genes GJA4, HOXA1, HOXA3, HOXB3, HEY2, GBX2, and SEMA3A were all prevented from being activated in iEC treated with TLR3 knockdown but not so in the scramble-treated iEC ( Figure VH in the online-only Data Supplement).
To further elucidate the elements of TLR3 signaling involved in transdifferentiation, we inhibited the action of downstream effector nuclear factor-κB using a decoy oligonucleotide. Nuclear factor-κB is a transcriptional effector of TLR3 activation 22, 23 and interacts with CBP/p300 to positively regulate gene expression. The number of iECs generated by the induction/transdifferentiation protocol ( Figure 5H ) was markedly reduced by the addition of p65 decoy. A similar result was observed when we repeated our transdifferentiation studies using tail-tip fibroblasts of TLR3 knockout or wild-type littermates. There was a 50% reduction in the mouse iECs generated by TLR3 knockout fibroblasts compared with wild-type fibroblasts ( Figure VI in the online-only Data Supplement).
Discussion
The salient observations of this study are as follows: (1) A small-molecule agonist of TLR3, combined with endothelial growth factors, is sufficient to transdifferentiate human fibroblasts to iECs that are morphologically and immunohistochemically similar to HMVECs. (2) The iECs share a transcriptional profile that is highly similar to that of HMVECs and, when administered to the ischemic hindlimb, are as effective as HMVECs in improving limb perfusion and reducing tissue injury. (3) The generation of effective iECs with the use of this small-molecule methodology is dependent on innate immune signaling. When fibroblasts were not exposed to the induction medium (ie, containing Poly I:C), endothelial growth medium (transdifferentiation medium) had no effect. Furthermore, TLR3 or nuclear factor-κB knockdown each reduced the generation of iECs with the use of this protocol.
Previously, we showed that activation of innate immunity increased epigenetic plasticity to enhance the action of cellpermeant transcriptional factors to induce the gene network required for pluripotency. In the present study, we used the combination of immunity-induced epigenetic plasticity and outside-in signaling to induce transdifferentiation of fibroblasts to ECs. The fact that epigenetic plasticity, combined with outside-in signaling, is sufficient for transdifferentiation to a therapeutic cell type is a conceptual departure and a technical advance. Previous studies have demonstrated the conversion of fibroblasts into angioblast-like cells 24 or ECs. 25, 26 However, the reported methods include either the use of transcription factors encoding Oct4, Sox2, Klf4, and cMyc 24, 26 or Oct4 and Klf4. 25 To our knowledge, this is also the first time that transdifferentiation to a therapeutic cell type has been accomplished with a small-molecule approach alone. It is likely that modifications of this small-molecule approach may be used to generate other somatic cells of therapeutic interest. 
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Generation of functional human ECs could be beneficial for various vascular disorders including wound healing and ischemic syndromes. Our previous studies have shown that ECs can be derived from pluripotent stem cells such as embryonic stem cells 11 or iPSCs. 21 These embryonic stem cells-ECs and iPSC-ECs are effective at increasing microvascular density and improving perfusion when administered to ischemic tissue. These effects appear to be mediated largely by paracrine effects of the cells rather than a direct contribution to the capillary bed. 21 However, generating human iPSCs, and deriving ECs from them, is cumbersome. For therapeutic purposes, such iPSC-ECs must be free of pluripotent cells that could induce teratoma formation. Accordingly, direct reprogramming to ECs is an attractive alternative approach, and, indeed, several groups have been successful in generating functional ECs directly from human fibroblasts. 6, 7 However, these groups used viral vectors encoding transcription factors, which raises concerns regarding integration of viral DNA into the reprogrammed cells.
We hypothesized that transdifferentiation might be achieved using small molecules exclusively. Our strategy was to activate innate immunity to induce epigenetic plasticity and to provide microenvironmental cues to promote endothelial lineage. We used the TLR3 agonist Poly I:C, which has been approved for preclinical use and has potential for use as a clinical-grade adjuvant. 27, 28 In addition, we used growth factors (VEGF, basic fibroblast growth factor, bone morphogenetic protein-4), 8-Br-cAMP, and the transforming growth factor-β inhibitor SB431542. This empirical formulation is based on literature indicating the role of these growth factors in endothelial development, endothelial proliferation, and prevention of endothelial-to-mesenchyme transformation. 6, 14, 29 Although our yield of iECs was modest (≈2%), our yield is not substantially different from those reported by others using viral constructs encoding transcriptional factors. We intend to perform high-throughput screening of small molecules that can increase this yield.
With respect to the other cells that may be generated by this protocol, we used markers for mesodermal, endodermal, and ectodermal lines (eg, CD45, CD14, CD41, Tau, Tuj1, runx2, α-actinin, α-MHC, and brachyury). We did not observe any increase in these markers over the course of the 28 days during our transdifferentiation protocol. Furthermore, we were not able to detect any c-kit or CD34-positive cells (which includes the subset of "endothelial progenitor cells") during the process of transdifferentiation during temporal studies of gene expression ( Figure VII in the online-only Data Supplement). Importantly, we performed quantitative PCR for EC markers for the entire 28 days of the transdifferentiation protocol. For each day, RNA was collected after human fibroblasts were treated through the various stages of treatment. We then checked for EC markers, specifically, CD31, CD144, KDR, and eNOS ( Figure VIII in the online-only Data Supplement). Intriguingly, KDR is the first of these to increase in expression at ≈14 days (KDR is known to be an earlier marker in endothelial development), followed by CD144, CD31, and lastly eNOS. The data suggest that, during the transdifferentiation, there is an epigenetic resistance that is greater for some endothelial genes than for others. The mechanism(s) of such epigenetic resistance may be an interesting topic for further study.
Previous studies have assigned detrimental roles to TLRs in the progression of atherosclerosis. However, Cole et al 30 found that deficiency of TLR3 accelerated the onset of atherosclerosis in hypercholesterolemic apolipoprotein E −/− mice. This finding suggests a protective role for TLR signaling in the vessel wall. 30 Taken together, our work and the observations of Cole and colleagues might indicate that some amount of immune activation is necessary for endothelial regeneration and repair.
The iECs we generated did not incorporate into the murine microvasculature. Nevertheless, we observed a significant increase in capillary density and an improvement in limb blood flow. We therefore assume that the effect of the injected human cells in the murine model of hindlimb ischemia is due to a paracrine effect rather than stable integration of the human cells into the murine limb vasculature.
We confirmed the role of innate immune activation in transdifferentiation using shRNA knockdown of TLR3. The knockdown of TLR3 reduced the yield of iECs. It is not surprising that we were still able to generate some iECs in this fibroblast line because the TLR knockdown is incomplete. Furthermore, Poly I:C can also activate innate immunity through the alternate RIG-I pathway. 31, 32 In the present investigation, we used the TLR3 agonist Poly I:C to activate innate immune signaling and epigenetic plasticity. However, we have unpublished evidence indicating that activation of other receptors involved in innate immune signaling, such as TLR4 and RIG-I, are also capable of inducing epigenetic plasticity. We speculate that any activation of innate immunity, triggered by pathogen-associated molecular patterns or damage-associated molecular patterns, induces global changes in epigenetic modifiers to increase epigenetic plasticity. We further speculate that this response permits cells to respond rapidly to microenvironmental cues, with a phenotypic plasticity that facilitates cellular response to pathogens or injury. We call this process transflammation.
Of great interest, the iECs derived from the knockdown lines were incompletely reprogrammed, as assessed by functional studies. Their abilities to incorporate acetylated LDL and to form a tubular network in Matrigel were markedly inhibited. These findings would be consistent with an incomplete activation of epigenetic plasticity and impaired reprogramming in the TLR3 knockdown lines. The role of innate immunity was further confirmed by our studies with the use of the decoy oligonucleotide against p65. In these studies, the decoy oligonucleotide also suppressed the generation of iECs. Taken together, our observations are consistent with the hypothesis that activation of innate immunity induces a state of epigenetic plasticity in which external cues can guide transdifferentiation. This concept may be useful in its application to the derivation of other cell types by transdifferentiation. In addition, our work provides a new avenue for therapeutic transdifferentiation with the use of small molecules in the absence of viral vectors or transcription factors, an approach that may be more feasible in vivo.
CLINICAL PERSPECTIVE
In Kafka's Metamorphosis, the protagonist wakes up one morning transformed into a beetle. Similarly, somatic cells are known to undergo dramatic changes in phenotype, typically in disease conditions. For example, in patients with gastroesophageal reflux, the chronic exposure to acid and inflammation is associated with Barrett's esophagus, preneoplastic changes in the squamous epithelial cells, as they assume a cuboidal morphology. However, transdifferentiation of somatic cells does not always lead to pathology. Recent evidence suggests that ischemia may cause the transdifferentiation of fibroblasts to endothelial cells, which may contribute to expansion of the microvasculature. This form of angiogenesis may have beneficial effects. Previous groups have induced such transdifferentiation using viral vectors encoding transcription factors so as to generate induced endothelial cells. The present article reports the first successful use of small molecules to generate induced endothelial cells from human fibroblasts. Specifically, we used an agonist of toll-like receptor 3 together with small molecules that promote endothelial lineage. This approach was based on our previous observation that activation of innate immune signaling causes an epigenetic plasticity that permits cell fluidity. Our work shows proof of concept for a pharmaceutical approach to cellular therapy that will promote revascularization. One clinical target might be the patient immediately after myocardial infarction. In this scenario, a small-molecule cocktail for promoting induced endothelial cell generation would transform some of the cardiac fibroblasts in the field of injury into endothelial cells that would self-assemble into a microvasculature that would provide the nutrition and the niche for cardiac repair rather than scar.
Supplementary Information
Figure Legends RNA-seq data shows that most of upregulated genes observed in scramble-iECs associated with endothelial biology are reversed in the TLR3KD-iECs. A variety of genes whose expression was activated in iEC was prevented by anti-TLR3 but unaffected by the scrambled vector. For example, angiogenesis essential genes GJA4, HOXA1, HOXA3, HOXB3, HEY2, GBX2, and SEMA3A were all prevented from being activated in iEC treated with TLR3 KD but not so in the scrambled-treated iEC. For the assessment gene expression similarities between iEC and HMVEC, we identified genes from the ANOVA performed in Figure 3 that were more strongly expressed in both iEC and HMVEC as compared to parental fibroblasts Subsequently, using Toppgene (http://toppgene.cchmc.org/), we used its Fisher's Exact test function to assess the enrichment of that set of genes for its enrichment for genes known to be associated with endothelial and angiogenic biology. HOXA-AS2  HOXA1  HOXA3  PNMT  HOXB4  SHISA3  TCL1B  WFIKKN1  WDR86  TPPP3  DNAH11  GADD45G  SEMA3E  PRKCQ-AS1  ZNF423  ADM5  HOXA2  C14orf39  HEY2  PTPRZ1  RHBDL3  RP11-5N23.2  ARHGDIG  RP11-126K1.6  MLLT4-AS1  RNU1-39P  SUGT1P3  GJA4  MMRN2  PLVAP  GBX2  SKP1P1  SSUH2  TMEM215  CNTFR  CCDC150  ARC  FXYD6  SYT6  TTYH1  LAMP5  RBP1  RBM38  BVES  HOTAIRM1  ANK3  ADAMTS9  HOXB3  HAGLR  HOXD1  SNCG  TMEM88 Fibroblast*(1)* Fibroblast*(2)* HMVEC* iEC*(1)* iEC*(2)* TLR3KD:iECs* Scram:iECs* * 
